pNfH is a promising biomarker for ALS
2013 (English)In: Amytrophic Lateral Sclerosis and Frontotemporal degeneration, ISSN 2167-8421, Vol. 14, no 2, 146-149 p.Article in journal (Refereed) Published
A diagnostic biomarker for ALS would permit early intervention with disease-modifying therapies while a biomarker for disease activity could accelerate the pace of drug discovery by facilitating shorter, and less costly, drug trials to be conducted with a smaller number of patients. Neurofilaments are the most abundant neuronal cytoskeletal protein. We set out to determine whether pNfH was a credible biomarker for ALS. pNfH levels were determined using an ELISA for 150 ALS subjects and 140 controls. We demonstrated a seven-fold elevation in the cerebrospinal fluid (CSF) levels of phosphorylated neurofilament heavy subunit (pNfH) in ALS (median n = 2787 pg/ml, n = 150), compared to headache and other benign controls (3 (4 pg/ml, n = 100, p = < 0.05). There was a 10-fold elevation of pNfH compared to ALS mimics (266 pg/ml, n = 20) and other neurodegenerative and inflammatory conditions (27 (pg/ml for n = 20) which was also highly significant (p = < 0.05). pNfH achieved a diagnostic sensitivity of 90% and specificity of 87% in distinguishing ALS from all controls. We also detected an inverse correlation between CSF pNfH levels and disease duration (time from symptom onset to death, r(2) = 0.1247, p = 0.001). In conclusion, pNfH represents a promising candidate for inclusion in a panel of diagnostic and prognostic biomarkers.
Place, publisher, year, edition, pages
Informa Healthcare, 2013. Vol. 14, no 2, 146-149 p.
Neurofilament heavy chain, biomarker, amyotrophic lateral sclerosis
IdentifiersURN: urn:nbn:se:umu:diva-67791DOI: 10.3109/21678421.2012.729596ISI: 000315416500012OAI: oai:DiVA.org:umu-67791DiVA: diva2:614232